Previous 10 | Next 10 |
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Synaptogenix Inc. (SNPX) is expected to report for Q1 2024
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology PR Newswire Acquires 25% stake in Cannasoul Analytics for up to $4 million to support R&D for cannabinoid- and psilocybin mushroom-based th...
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease PR Newswire Bryostatin-1 benefits in severe Alzheimer's disease patients we...
2023-09-07 10:50:46 ET Penny Stocks: High Risk, High Reward Penny stocks, typically priced below $5, have become a popular choice for day traders due to their potential for rapid gains. These stocks can offer market-beating returns in a short period, making them attractive for those loo...
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study PR Newswire Positive changes in ALS gene expression and increased cellular viability met with statistical significance of p<.001 NEW YORK ...
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis PR Newswire Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health...
2023-07-14 06:21:00 ET 3 Questions About Penny Stocks: Answered for 2023 Penny stocks, often undervalued by the mainstream investment world, present a unique opportunity for those willing to explore the less trodden paths of the financial markets. As we navigate through 2023, the penn...
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience PR Newswire Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint...
Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities PR Newswire Announces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients Maintains strong finan...
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Inc. Company Name:
SNPX Stock Symbol:
OTCMKTS Market:
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR Newswire Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways ...